• +41 91 682 20 40
  • info@elixi-int.com
  • Reserved Area
    • Login
    • Register
    • Request Document
    • Send Document
logo
  • Home
  • About Us
  • Services
  • Quality
  • News
  • Case Studies
  • Contact

Let's talk

info@yourwebsite.com
+1 (555) 123-4567

  • Search

Elixi

26 January 2021

RINVOQ™ (Upadacitinib), approved for the Treatment of Psoriatic Arthritis and Ankylosing Spondylitis


0 Comments3 Minutes

19 January 2021

XALKORI (CRIZOTINIB) approved for ALK-POSITIVE anaplastic large cell LYMPHOMA in children and young adults


0 Comments2 Minutes

18 January 2021

Enhertu (trastuzumab deruxtecan) first HER2-directed medicine approved in a decade for patients with HER2-positive metastatic gastric cancer


0 Comments3 Minutes

12 January 2021

Xofluza® (baloxavir marboxil), a first-in-class, single-dose oral medicine, for the treatment of influenza,


0 Comments3 Minutes

8 January 2021

Glucagon for injection USP, First Generic of Drug Used to Treat Severe Hypoglycemia


0 Comments4 Minutes

5 January 2021

Ibrance, Palbociclib, is the #1 prescribed, FDA-approved oral combination treatment for HR+, HER2- mBC.


0 Comments2 Minutes

22 December 2020

Libmeldy, world’s first lentiviral vector-based gene therapy for the treatment of metachromatic leukodystrophy (MLD)


0 Comments5 Minutes

21 December 2020

PALFORZIA® [defatted powder of Arachis hypogaea L., semen (peanuts)]approved in the EU for the treatment of peanut allergy


0 Comments1 Minutes

19 December 2020

Tagrisso (osimertinib) , First Adjuvant Therapy for Most Common Type of Lung Cancer


0 Comments2 Minutes

3 December 2020

Gallium 68 PSMA-11 (Ga 68 PSMA-11)is the First PSMA-Targeted PET Imaging Drug for Men with Prostate Cancer


0 Comments3 Minutes

  • 1
  • …
  • 3
  • 4
  • 5
  • 6
  • 7
  • …
  • 13

Warning:

A cybersecurity incident is under investigation. Please be carefull with emails or phone calls that correctly mention your name, role, or current transactions. Elixi’s crisis team is working to limit any harmful impact, as the security of our clients’ and suppliers’ data is Elixi’s top priority. For any clarification, you can contact: DPO@elixi-int.com

Si è verificato un evento di sicurezza informatica in corso di analisi. Vi invitiamo a prestare massima attenzione messaggi di posta elettronica o telefonate che citano correttamente il vostro nome, la funzione o operazioni realmente avvenute. Il crisis team di Elixi sta lavorando per limitare ogni conseguenza dannosa, perchè la sicurezza dei dati dei nostri clienti e dei fornitori è la nostra priorità di Elixi. Per ogni chiarimento potete contattare: DPO@elixi-int.com